Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2

Cancer Journal from Scientific American

Volumn 6, Issue SUPPL. 1, 2000, Pages

  Shimizu, Koichi ^a   Fields, Ryan C ^a,b   Redman, Bruce G ^c   Giedlin, Martin ^d   Mulé, James J ^a,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cancer vaccines; Dendritic cells; Immunotherapy; Interleukin 2

Indexed keywords

RECOMBINANT INTERLEUKIN 2; TUMOR VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR ANTIGEN;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLORECTAL CANCER; DENDRITIC CELL; IMMUNE RESPONSE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; T LYMPHOCYTE; TUMOR REGRESSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; IMMUNIZATION; TUMOR;

ANIMALS; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNIZATION; INTERLEUKIN-2; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; SARCOMA, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033839912     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. O'Donnell RW, Marquis DM, Mudholkar GS et al. In vivo enhancement of antitumor immunity by interleukin 2-rich lymphokines. Cancer Res 1986;46:3273-3278.
2. Stidham KR, Ricci WM, Vervaert C et al. Modulation of specific active immunization against murine melanoma using recombinant cytokines. Surg Oncol 1996;5:221-229.
3. Arroyo PJ, Bash JA, Wallack MK. Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon alpha in a murine hepatic metastasis model. Cancer Immunol Immunother 1990;31:305-311.
4. Barnavon Y, Iwaki H, Bash JA et al. Treatment of murine hepatic metastases with vaccinia colon oncolysates and IL-2. J Surg Res 1988;45:523-530.
5. Sivanandham M, Scoggin SD, Tanaka N et al. Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model. Cancer Immunol Immunother 1994;38:259-264.
6. Bronte V, Tsung K, Rao JB et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 1995;154:5282-5292.
7. McLaughlin JP, Schlom J, Kantor JA et al. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res 1996;56:2361-2367.
8. Weinberg A, Merigan TC. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines. J Immunol 1988;140: 294-299.
9. Perrin P, Joffret ML, Leclerc C et al. Interleukin 2 increases protection against experimental rabies. Immunobiology 1988;177: 199-209.
10. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-296.
11. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245-3287.
12. Cohen PJ, Cohen PA, Rosenberg SA et al. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. Eur J Immunol 1994;24:315-319.
13. Cohen PA, Cohen PJ, Rosenberg SA et al. CD4+ T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens. Cancer Res 1994;54:1055-1058.
14. Fields RC, Shimizu K, Mulé JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998;95: 9482-9487.
15. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996;156:2918-2926.
16. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med 1995;1: 1297-1302.
17. Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997;186:1183-1187.
18. Paglia P, Chiodoni C, Rodolfo M et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996;183:317-322.
19. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996;184:465-472.
20. Condon C, Watkins SC, Celluzzi CM et al. DNA-based immunization by in vivo transfection of dendritic cells. Nature Med 1996;2:1122-1128.
21. Manickan E, Kanangat S, Rouse RJ, Yu Z, Rouse BT. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. J Leukoc Biol 1997;61:125-132.
22. Chen B, Shi Y, Smith JD et al. The role of tumor necrosis factor alpha in modulating the quantity of peripheral blood-derived, cytokine-driven human dendritic cells and its role in enhancing the quality of dendritic cell function in presenting soluble antigens to CD4+ T cells in vitro. Blood 1998;91:4652-4661.
23. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179:1109-1118.
24. Arca MJ, Krauss JC, Aruga A et al. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther 1996;3:39-47.
25. Tanaka K, Hayashi H, Hamada C et al. Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells. Proc Nad Acad Sci USA 1986;83:8723-8727.
26. Tanaka K, Isselbacher KJ, Khoury G, Jay G. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 1985;228:26-30.
27. Geraghty P, Fields R, Mule J. Vaccination with tumor-pulsed splenic dendritic cells mediates immunity to a poorly immunogenic tumor. Surg Forum 1996;47:459.
28. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med 1998;4:328-332.
29. Rosenberg SA, Mulé JJ, Spiess PJ et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985;161:1169-1188.
30. Mulé JJ, Yang JC, Afreniere RL et al. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol 1987;139:285-294.
31. Lotze MT, Chang AE, Seipp CA et al. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA 1986;256:3117-3124.
32. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 1986;137:1735-1742.
33. Urba WJ, Steis RG, Longo DL et al. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer. Cancer Res 1990;50:185-192.
34. McIntosh JK, Mulé JJ, Krosnick JA et al. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice. Cancer Res 1989;49:1408-1414.
35. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998;4:321-327.
36. Henry F, Boisteau O, Bretaudeau L et al. Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res 1999;59:3329-3332.
37. Henry F, Bretaudeau L, Barbieux I et al. Induction of antigen presentation by macrophages after phagocytosis of tumour apoptotic cells. Res Immunol 1998;149:673-679.
38. Earth RJ Jr, Mulé JJ, Spiess PJ et al. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 1991; 173:647-658.